Creative Biolabs, a world-leading service provider in the field of antibody development, now is very proud of providing high-quality non-IgG antibodies development services for clients all over the world. Currently, non-IgG antibodies against many stomach carcinoma antigens are available in our laboratory.
Stomach Carcinoma
Stomach cancer, also known as gastric cancer, is an epithelial-derived malignant tumor that usually develops from the mucus-producing cells. Most gastric carcinomas form glands, also known as gastric adenocarcinoma or adenocarcinoma of the stomach. Although the cause of stomach cancer is not clear, several risk factors may be associated with the occurrence including smoking, infection with Helicobacter pylori (H. pylori) bacteria, diet, and certain inherited conditions. Currently, stomach cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancer death in the world, accounting for 7% of all cases and 9% of all deaths. The commonly used treatments for gastric cancer include surgery (preferred choice for early diagnosis), chemotherapy and/or radiation treatment. In order to improve the survival rate, monoclonal antibodies based immunotherapies have been developed for the stomach carcinoma target treatment, all of which are IgG antibodies (several have been approved and many are in pre-clinical research) and few are non-IgG isotype. Recent studies have implicated that non-IgG antibodies (mainly IgM isotype) may be an alternative to IgG antibodies, exerting certain advantages over IgG antibodies.
Fig.1 Current targeted therapy and oncogenic pathways in gastric cancer. (Kiyozumi, 2018)
IgM antibodies for Stomach Carcinoma Treatment
IgM is one of the five classes of human antibodies produced by the immune system as well as the largest isotype in structure. It is the first antibody produced in the body in response to infection. In normal serum, IgM is often found to bind to specific antigens, even in the absence of prior immunization. A study has shown thousands of tumor-reactive human antibodies isolated from cancer patients and healthy donors are the IgM isotype, not IgG and IgA isotype. And all of these antibodies can bind to carbohydrates on modified tumor-specific receptors and induce apoptosis. These data suggest IgM antibody plays an important role in immunosurveillance mechanisms against several tumors in humans. Moreover, a human natural IgM antibody (SC-1) has been demonstrated to induce apoptosis in signet ring cell stomach carcinomas both in vivo and in vitro by specifically binding to tumor-specific carbohydrate epitope of decay acceleration factor-B expressed on the stomach carcinoma cells.
Non-IgG Therapeutic Antibodies at Creative Biolabs
As a pioneer in the field of antibody development, Creative Biolabs is more than happy to provide the best and fully comprehensive services of antibody development including polyclonal, monoclonal, and recombinant antibody development. On the basis of existing experience and expertise, our experts have engaged in non-IgG antibodies development for many years. Based on the advanced and powerful technical platforms, we are confident in providing the best services about non-IgG antibodies against stomach carcinoma. For any questions, please feel free to contact us. Our scientists will support you with the best solution.
Reference
- Kiyozumi, Y.; et al. Update on targeted therapy and immune therapy for gastric cancer, 2018. Journal of Cancer Metastasis and Treatment. 2018, 4: 31.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.